Literature DB >> 15070264

Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.

Mark J Rivard1, Bert M Coursey, Larry A DeWerd, William F Hanson, M Saiful Huq, Geoffrey S Ibbott, Michael G Mitch, Ravinder Nath, Jeffrey F Williamson.   

Abstract

Since publication of the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report in 1995 (TG-43), both the utilization of permanent source implantation and the number of low-energy interstitial brachytherapy source models commercially available have dramatically increased. In addition, the National Institute of Standards and Technology has introduced a new primary standard of air-kerma strength, and the brachytherapy dosimetry literature has grown substantially, documenting both improved dosimetry methodologies and dosimetric characterization of particular source models. In response to these advances, the AAPM Low-energy Interstitial Brachytherapy Dosimetry subcommittee (LIBD) herein presents an update of the TG-43 protocol for calculation of dose-rate distributions around photon-emitting brachytherapy sources. The updated protocol (TG-43U1) includes (a) a revised definition of air-kerma strength; (b) elimination of apparent activity for specification of source strength; (c) elimination of the anisotropy constant in favor of the distance-dependent one-dimensional anisotropy function; (d) guidance on extrapolating tabulated TG-43 parameters to longer and shorter distances; and (e) correction for minor inconsistencies and omissions in the original protocol and its implementation. Among the corrections are consistent guidelines for use of point- and line-source geometry functions. In addition, this report recommends a unified approach to comparing reference dose distributions derived from different investigators to develop a single critically evaluated consensus dataset as well as guidelines for performing and describing future theoretical and experimental single-source dosimetry studies. Finally, the report includes consensus datasets, in the form of dose-rate constants, radial dose functions, and one-dimensional (1D) and two-dimensional (2D) anisotropy functions, for all low-energy brachytherapy source models that met the AAPM dosimetric prerequisites [Med. Phys. 25, 2269 (1998)] as of July 15, 2001. These include the following 125I sources: Amersham Health models 6702 and 6711, Best Medical model 2301, North American Scientific Inc. (NASI) model MED3631-A/M, Bebig/Theragenics model I25.S06, and the Imagyn Medical Technologies Inc. isostar model IS-12501. The 103Pd sources included are the Theragenics Corporation model 200 and NASI model MED3633. The AAPM recommends that the revised dose-calculation protocol and revised source-specific dose-rate distributions be adopted by all end users for clinical treatment planning of low energy brachytherapy interstitial sources. Depending upon the dose-calculation protocol and parameters currently used by individual physicists, adoption of this protocol may result in changes to patient dose calculations. These changes should be carefully evaluated and reviewed with the radiation oncologist preceding implementation of the current protocol.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15070264     DOI: 10.1118/1.1646040

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  298 in total

1.  Impact of source-production revision on the dose-rate constant of 131Cs interstitial brachytherapy sources.

Authors:  Zhe Chen; Paul Bongiorni; Ravinder Nath
Journal:  Med Phys       Date:  2010-07       Impact factor: 4.071

2.  PROBABILISTIC NON-RIGID REGISTRATION OF PROSTATE IMAGES: MODELING AND QUANTIFYING UNCERTAINTY.

Authors:  Petter Risholm; Andriy Fedorov; Jennifer Pursley; Kemal Tuncali; Robert Cormack; William M Wells
Journal:  Proc IEEE Int Symp Biomed Imaging       Date:  2011-06-09

3.  Visual acuity, oncologic, and toxicity outcomes with 103Pd vs. 125I plaque treatment for choroidal melanoma.

Authors:  Kirtesh R Patel; Roshan S Prabhu; Jeffrey M Switchenko; Mudit Chowdhary; Caroline Craven; Pia Mendoza; Hasan Danish; Hans E Grossniklaus; Thomas M Aaberg; Thomas Aaberg; Sahitya Reddy; Elizabeth Butker; Chris Bergstrom; Ian R Crocker
Journal:  Brachytherapy       Date:  2017-03-03       Impact factor: 2.362

4.  A systematic evaluation of the dose-rate constant determined by photon spectrometry for 21 different models of low-energy photon-emitting brachytherapy sources.

Authors:  Zhe Jay Chen; Ravinder Nath
Journal:  Phys Med Biol       Date:  2010-09-24       Impact factor: 3.609

5.  A Monte Carlo study of I-125 prostate brachytherapy with gold nanoparticles: dose enhancement with simultaneous rectal dose sparing via radiation shielding.

Authors:  D Brivio; P L Nguyen; E Sajo; W Ngwa; P Zygmanski
Journal:  Phys Med Biol       Date:  2017-01-31       Impact factor: 3.609

6.  Ice as a water-equivalent solid medium for brachytherapy dosimetric measurements.

Authors:  Haijun Song; Zhe Chen; Ning Yue; Qingrong Wu; Fang-Fang Yin
Journal:  Radiat Environ Biophys       Date:  2008-12-09       Impact factor: 1.925

7.  Evaluation of Gafchromic EBT2 film for the measurement of anisotropy function for high-dose-rate (192)Ir brachytherapy source with respect to thermoluminescent dosimetry.

Authors:  Satish C Uniyal; Umesh C Naithani; Sunil D Sharma
Journal:  Rep Pract Oncol Radiother       Date:  2010-12-07

8.  Differential dose contributions on total dose distribution of (125)I brachytherapy source.

Authors:  B Camgöz; G Yeğin; M N Kumru
Journal:  Rep Pract Oncol Radiother       Date:  2010-05-26

9.  Air kerma strength characterization of a GZP6 Cobalt-60 brachytherapy source.

Authors:  Mohammad Taghi Bahreyni Toossi; Mahdi Ghorbani; Ali Asghar Mowlavi; Mojtaba Taheri; Mohsen Layegh; Yasha Makhdoumi; Ali Soleimani Meigooni
Journal:  Rep Pract Oncol Radiother       Date:  2010-11-09

10.  Dosimetric characterization of the GammaClip™ 169Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection.

Authors:  Blake Currier; John J Munro; David C Medich
Journal:  Med Phys       Date:  2013-08       Impact factor: 4.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.